2017/4 GaBI Journal Table of Contents

Published in: Volume 6 / Year 2017 / Issue 4
Category: 2017/4 GaBI Journal Table of Contents
Visits: 219 total, 2 today

Contents

Editor’s Letter

Fourth and final issue of GaBI Journal’s sixth volume

Letters to the Editor

Clear naming, traceability of biological medicines will protect patients

Comment on the non-biological complex drugs paper

Commentary

Global policies on pharmacy-mediated substitution of biosimilars: a summary

Original Research

Pharmacy-mediated substitution of biosimilars – a global survey benchmarking country substitution policies

Review Article

Major lessons learned from Zarxio’s US launch: the start of a biosimilar revolution

Perspective

40th anniversary of essential medicines: a loud call for improving its access

Guidelines

Biosimilars in Germany: guidance of the Drug Commission of the German Medical Association

Special Report

Building stakeholder confidence in biosimilar medicines through evidence-based information sharing

USA and Europe differ in interchangeability of biosimilars

Meeting Report

Perspectives on the future of pegfilgrastim biosimilars

Abstracted Scientific Content

Randomized non-inferiority trial fails to find inferiority switching from infliximab originator to CT-P13 biosimilar

A comparison of European and US generic drug markets

Research News

HIV patients will accept generic treatments

Go Back Print

Leave a Reply